Universidad San Sebastián  
 

Repositorio Institucional Universidad San Sebastián

Búsqueda avanzada

Descubre información por...

 

Título

Ver títulos
 

Autor

Ver autores
 

Tipo

Ver tipos
 

Materia

Ver materias

Buscar documentos por...




Mostrar el registro sencillo del ítem

dc.contributor.author Cárcamo-Lemus, Natali
dc.contributor.author Bernier, Angelo
dc.contributor.author Oporto-Ortega, Ivana
dc.contributor.author San Martin San Martin, Alejandro Antonio
dc.contributor.author Sandoval Oporto, Pamela Yohana
dc.date.accessioned 2026-02-08T03:37:05Z
dc.date.available 2026-02-08T03:37:05Z
dc.date.issued 2025-11-20
dc.identifier.issn 1860-6768
dc.identifier.uri https://repositorio.uss.cl/handle/uss/20843
dc.description Publisher Copyright: © 2025 Wiley-VCH GmbH.
dc.description.abstract Increasing evidence supports the human sodium-coupled citrate transporter (hNaCT) as a potential therapeutic target for metabolic syndrome and early infantile epileptic encephalopathy type 25 (EIEE25). While isotopic tracers remain the reference method for evaluating citrate transport, the need for specialized equipment and regulatory approval restricts their widespread use. Here, we report the development and validation of a robust, fluorescent-based assay to evaluate hNaCT-mediated citrate transport in live cells at both single-cell and high-throughput levels. This method utilizes a baculoviral vector to modify HEK293 cells to co-express a genetically encoded citrate sensor (Citron1) and the hNaCT. This cell-based platform enabled real-time monitoring of citrate transport using fluorescent microscopy and a standard multiwell plate reader. A key strength of this approach is its ability to assess citrate transport in the same cells before and after experimental interventions. Accordingly, this approach enables the functional characterization of hNaCT, including its pharmacological inhibitors and genetic variants with altered activity. Overall, the method provides a reliable assessment of citrate transport and offers a versatile platform suitable for identifying novel lead compounds for the therapeutic modulation of hNaCT. en
dc.description.abstract Increasing evidence supports the human sodium-coupled citrate transporter (hNaCT) as a potential therapeutic target for metabolic syndrome and early infantile epileptic encephalopathy type 25 (EIEE25). While isotopic tracers remain the reference method for evaluating citrate transport, the need for specialized equipment and regulatory approval restricts their widespread use. Here, we report the development and validation of a robust, fluorescent-based assay to evaluate hNaCT-mediated citrate transport in live cells at both single-cell and high-throughput levels. This method utilizes a baculoviral vector to modify HEK293 cells to co-express a genetically encoded citrate sensor (Citron1) and the hNaCT. This cell-based platform enabled real-time monitoring of citrate transport using fluorescent microscopy and a standard multiwell plate reader. A key strength of this approach is its ability to assess citrate transport in the same cells before and after experimental interventions. Accordingly, this approach enables the functional characterization of hNaCT, including its pharmacological inhibitors and genetic variants with altered activity. Overall, the method provides a reliable assessment of citrate transport and offers a versatile platform suitable for identifying novel lead compounds for the therapeutic modulation of hNaCT. es
dc.language.iso eng
dc.relation.ispartof vol. 20 Issue: no. 11 Pages: 1
dc.source Biotechnology Journal
dc.title A Fluorescent-Based Method to Assess the Activity of the Human Sodium-Coupled Citrate Transporter en
dc.type Artículo
dc.identifier.doi 10.1002/biot.70156
dc.publisher.department Facultad de Medicina


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem